Workflow
ESCO Technologies(ESE)
icon
Search documents
ESCO Technologies(ESE) - 2025 Q2 - Quarterly Report
2025-05-09 16:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 1-10596 ESCO TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) MISSOURI 43-1554045 (State or other jurisdicti ...
ESCO Technologies(ESE) - 2025 Q2 - Earnings Call Transcript
2025-05-07 22:02
ESCO (ESE) Q2 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Kate Lowrey - VP-IRBryan Sayler - President & CEOChris Tucker - Senior Vice President and Chief Financial OfficerJon Tanwanteng - Managing DirectorTommy Moll - Managing Director Conference Call Participants Josh Sullivan - MD & Senior Equity Research Analyst Operator Good day, and welcome to the Q2 twenty twenty five ESCO Technologies, Inc. Earnings Conference Call. At this time, all participants are in a listen only mode. After ...
ESCO Technologies(ESE) - 2025 Q2 - Earnings Call Transcript
2025-05-07 22:00
ESCO (ESE) Q2 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good day, and welcome to the Q2 twenty twenty five ESCO Technologies, Inc. Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Kate Lowry, Vice President of Investor Relations. Please go ahead. Speak ...
ESCO Technologies(ESE) - 2025 Q2 - Earnings Call Presentation
2025-05-07 20:32
ESCO Technologies Second Quarter FY 2025 Earnings Call Bryan Sayler President & CEO Chris Tucker Sr. Vice President & CFO May 7, 2025 1 Forward Looking Statement Statements in this presentation regarding Management's intentions, expectations and guidance for fiscal 2025, including restructuring and cost reduction actions, sales, orders, revenues, margin, earnings, Adjusted EPS, acquisition related amortization, and any other statements which are not strictly historical, are "forward-looking statements" with ...
ESCO Technologies(ESE) - 2025 Q2 - Quarterly Results
2025-05-07 20:15
NEWS FROM Exhibit 99.1 For more information contact: Kate Lowrey - VP of Investor Relations (314) 213-7277 / klowrey@escotechnologies.com ESCO REPORTS SECOND QUARTER FISCAL 2025 RESULTS - Q2 Sales increase 7% to $266 Million - - Q2 GAAP EPS increases 33% to $1.20 - - Q2 Adjusted EPS increases 24% to $1.35 - - Q2 Orders increase 22% to $291 Million / Book-to-Bill of 1.10x - ST. LOUIS, May 7, 2025 – ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the second q ...
ESCO Reports Second Quarter Fiscal 2025 Results
GlobeNewswire· 2025-05-07 20:15
- Q2 Sales increase 7% to $266 Million - Q2 GAAP EPS increases 33% to $1.20 - Q2 Adjusted EPS increases 24% to $1.35 - Q2 Orders increase 22% to $291 Million / Book-to-Bill of 1.10x -St. Louis, May 07, 2025 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the second quarter ended March 31, 2025 (Q2 2025). Operating Highlights Q2 2025 Sales increased $16.4 million (7 percent) to $265.5 million compared to $249.1 million in Q2 2024.Q2 2025 ...
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
GlobeNewswire News Room· 2025-05-05 12:30
COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen. Four oral presentations will feature Ascendis clinical trial results, including 4-year effica ...
ESCO Completes Acquisition of SM&P
GlobeNewswire· 2025-04-28 12:30
SM&P will become part of ESCO's Aerospace & Defense (A&D) segment. Their Signature Management and Power Management product lines are highly complementary to ESCO's current naval programs. Signature Management offers solutions for surface ships and submarines that provide magnetic and electric field countermeasures to prevent underwater mine and sensor detection. Power Management provides innovative and highly-engineered motors that drive critical ship propulsion systems with an ultra-quiet design ensuring l ...
ESCO Technologies Announces Second Quarter 2025 Earnings Release and Conference Call
GlobeNewswire· 2025-04-21 20:15
St. Louis, April 21, 2025 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE:ESE) will report its second quarter financial results after the market close on Wednesday, May 7, 2025, followed by a conference call where the financial results and related commentary will be discussed. Event: Second Quarter 2025 Conference Call Date: Wednesday, May 7Time: 4:00 p.m. Central Time The conference call webcast and an accompanying slide presentation will be available in the Investor Center of ESCO’s website. The slide p ...
Has ESCO Technologies (ESE) Outpaced Other Industrial Products Stocks This Year?
ZACKS· 2025-03-28 14:40
The Industrial Products group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Esco Technologies (ESE) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Industrial Products sector should help us answer this question.Esco Technologies is a member of our Industrial Products group, which includes 200 different companies and currently sits at #10 in the Zacks Sector Rank. ...